Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record.

The Spectrum of Type I Cryoglobulinemia Vasculitis: New Insights Based on 64 Cases

Open access
Terrier, Benjamin, Karras, Alexandre, Kahn, Jean-Emmanuel, Le Guenno, Guillaume, Marie, Isabelle, Benarous, Lucas, Lacraz, Adeline, Diot, Elisabeth, Hermine, Olivier, de Saint-Martin, Luc, Cathébras, Pascal, Leblond, Véronique, Modiano, Philippe, Léger, Jean-Marc, Mariette, Xavier, Senet, Patricia, Plaisier, Emmanuelle, Saadoun, David, Cacoub, Patrice · 2013 · Medicine

Abstract

Type I cryoglobulinemia vasculitis (CryoVas) is considered a life-threatening condition; however, data on the characteristics and outcome are scarce. To analyze the presentation, prognosis, and efficacy and safety of treatments of type I CryoVas, we conducted a French nationwide survey that included 64 patients with type I CryoVas between January 1995 and July 2010: 28 patients with monoclonal gammopathy of unknown significance (MGUS) and 36 with hematologic malignancy.Type I monoclonal CryoVas was characterized by severe cutaneous involvement (necrosis and ulcers) in almost half the patients and high serum cryoglobulin levels, contrasting with a lower frequency of glomerulonephritis than expected. The 1-, 3-, 5-, and 10-year survival rates were 97%, 94%, 94%, and 87%, respectively. Compared to MGUS, type I CryoVas related to hematologic malignancy tended to be associated with a poorer prognosis. Therapeutic regimens based on alkylating agents, rituximab, thalidomide or lenalinomide, and bortezomib showed similar efficacy on vasculitis manifestations, with clinical response rates from 80% to 86%.Data from the CryoVas survey show that the prognosis of type I CryoVas does not seem to be as poor as previously suggested. Besides alkylating agents, the use of regimens based on rituximab, thalidomide or lenalinomide, and bortezomib are interesting alternative options, although the exact role of each strategy remains to be defined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0b013e318288925c

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 207

Metadata

Authors
Terrier, B., Karras, A., Kahn, J.-E., Le Guenno, G., Marie, I., Benarous, L., Lacraz, A., Diot, E., Hermine, O., de Saint-Martin, L., Cathébras, P., Leblond, V., Modiano, P., Léger, J.-M., Mariette, X., Senet, P., Plaisier, E., Saadoun, D., & Cacoub, P.
Venue
Medicine
Published
2013-03
Volume
92
Issue
2
Pages
61-68
ISSN
0025-7974 (ISSN-L)
OpenAlex
W2028587572
Cited by
207
References
0
FWCI
11.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Spectrum of Type I Cryoglobulinemia Vasculitis: New Insights Based on 64 Cases. https://app.cochat.ai/papers/10.1097/md.0b013e318288925c
The paper
Terrier, B., Karras, A., Kahn, J.-E., Le Guenno, G., Marie, I., Benarous, L., Lacraz, A., Diot, E., Hermine, O., de Saint-Martin, L., Cathébras, P., Leblond, V., Modiano, P., Léger, J.-M., Mariette, X., Senet, P., Plaisier, E., Saadoun, D., & Cacoub, P. (2013). The Spectrum of Type I Cryoglobulinemia Vasculitis: New Insights Based on 64 Cases. Medicine. https://doi.org/10.1097/md.0b013e318288925c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.